LIVER DISEASES

Peter FICKERT

SITE

BMC Pediatr. 2020;20:340. Histological demonstration of BSEP/ABCB11 inhibition in transient neonatal cholestasis: a case report. Baghdasaryan A, Ofner-Ziegenfuß L, Lackner C, Fickert P, Resch B, Morris NM, Deutschmann A. PubMed
Annu Rev Pharmacol Toxicol. 2020;60:503-527. Drug therapies for chronic cholestatic liver diseases. Wagner M, Fickert P. PubMed

Hepatol Commun. 2018;2:1550-1566. Calnexin depletion by endoplasmic reticulum stress during cholestasis inhibits the Na+-Taurocholate Cotransporting Polypeptide. Robin MJD, Appelman MD, Vos HR, van Es RM, Paton JC, Paton AW, Burgering B, Fickert P, Heijmans J, van de Graaf SFJ. PubMed

Biochim Biophys Acta Mol Basis Dis. 2019;1865:243-251. Bile acids and glucocorticoid metabolism in health and disease. Theiler-Schwetz V, Zaufel A, Schlager H, Obermayer-Pietsch B, Fickert P, Zollner G. PubMed

Liver Int. 2018;38:991-994. Time for the dawn of multimodal therapies and the dusk for mono-therapeutic trials for cholestatic liver diseases? Wagner M, Fickert P. PubMed

J Hepatol. 2017;67:619-631. Biliary bile acids in hepatobiliary injury - What is the link? Fickert P, Wagner M. PubMed

J Hepatol. 2017;67:549-558. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumpf E, Nevens F, Trivedi P, Reiter FP, Tornai I, Halilbasic E1, Greinwald R, Pröls M, Manns MP, Trauner M; European PSC norUDCA Study Group. PubMed

World J Hepatol. 2016;8:401-10. Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model. Reiter FP, Wimmer R, Wottke L, Artmann R, Nagel JM, Carranza MO, Mayr D, Rust C, Fickert P, Trauner M, Gerbes AL, Hohenester S, Denk GU. PubMed

J Hepatol. 2016;64:674-81. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. Baghdasaryan A, Fuchs CD, Österreicher CH, Lemberger UJ, Halilbasic E, Påhlman I, Graffner H, Krones E, Fickert P, Wahlström A, Ståhlman M, Paumgartner G, Marschall HU, Trauner M. PubMed

Digestion. 2014;90:81-8. Alterations of canalicular ATP-binding cassette transporter expression in drug-induced liver injury. Zollner G, Thueringer A, Lackner C, Fickert P, Trauner M. PubMed

Hepatol Int. 2014;8:443-52. Vitamin D modulates biliary fibrosis in ABCB4-deficient mice. Hochrath K, Stokes CS, Geisel J, Pollheimer MJ, Fickert P, Dooley S, Lammert F. PubMed

Drug Metab Dispos. 2014;42:1423-31. Inflammatory bowel disease alters intestinal bile acid transporter expression. Jahnel J, Fickert P, Hauer AC, Högenauer C, Avian A, Trauner M. PubMed

Digestion. 2012;86:244-9. Combined rifampicin and ursodeoxycholic acid treatment does not amplify rifampicin effects on hepatic detoxification and transport systems in humans. Marschall HU, Wagner M, Zollner G, Fickert P, Silbert D, Gustafsson U, Sahlin S, Trauner M. PubMed

Liver Int. 2012;32:119-27. Hepatobiliary transporter expression and post-operative jaundice in patients undergoing partial hepatectomy. Bernhardt GA, Zollner G, Cerwenka H, Kornprat P, Fickert P, Bacher H, Werkgartner G, Müller G, Zatloukal K, Mischinger HJ, Trauner M. PubMed

Hepatology. 2011;54:1303-12. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output. Baghdasaryan A, Claudel T, Gumhold J, Silbert D, Adorini L, Roda A, Vecchiotti S, Gonzalez FJ, Schoonjans K, Strazzabosco M, Fickert P, Trauner M. PubMed

Gastroenterology. 2012;142:140-151.e12. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Moustafa T, Fickert P, Magnes C, Guelly C, Thueringer A, Frank S, Kratky D, Sattler W, Reicher H, Sinner F, Gumhold J, Silbert D, Fauler G, Höfler G, Lass A, Zechner R, Trauner M. PubMed

Gut. 2010;59:521-30. doi: 10.1136/gut.2009.186528. Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, Thüringer A, Leski K, Fickert P, Karpen SJ, Trauner M. PubMed

Gastroenterology. 2010;138:2499-508. Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis. Mair M, Zollner G, Schneller D, Musteanu M, Fickert P, Gumhold J, Schuster C, Fuchsbichler A, Bilban M, Tauber S, Esterbauer H, Kenner L, Poli V, Blaas L, Kornfeld JW, Casanova E, Mikulits W, Trauner M, Eferl R. PubMed

Hepatology. 2009;50:893-9. The role of the hepatocyte cytokeratin network in bile formation and resistance to bile acid challenge and cholestasis in mice. Fickert P, Fuchsbichler A, Wagner M, Silbert D, Zatloukal K, Denk H, Trauner M. PubMed

Liver Int. 2009;29:1316-25. Impact of experimental colitis on hepatobiliary transporter expression and bile duct injury in mice. Jahnel J, Fickert P, Langner C, Högenauer C, Silbert D, Gumhold J, Fuchsbichler A, Trauner M. PubMed

Liver Int. 2008;28:948-58. Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice. Baghdasaryan A, Fickert P, Fuchsbichler A, Silbert D, Gumhold J, Hörl G, Langner C, Moustafa T, Halilbasic E, Claudel T, Trauner M. PubMed

Liver Int. 2007;27(7):920-9. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Zollner G, Wagner M, Fickert P, Silbert D, Gumhold J, Zatloukal K, Denk H, Trauner M. PubMed

Am J Pathol. 2007;171:525-36. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Fickert P, Stöger U, Fuchsbichler A, Moustafa T, Marschall HU, Weiglein AH, Tsybrovskyy O, Jaeschke H, Zatloukal K, Denk H, Trauner M. PubMed

Drug Metab Dispos. 2007;35:1694-9. Hepatobiliary transporter expression in intercellular adhesion molecule 1 knockout and Fas receptor-deficient mice after common bile duct ligation is independent of the degree of inflammation and oxidative stress. Wagner M, Zollner G, Fickert P, Gumhold J, Silbert D, Fuchsbichler A, Gujral JS, Zatloukal K, Denk H, Jaeschke H, Trauner M. PubMed

Semin Liver Dis. 2007;27:77-98. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Trauner M, Fickert P, Wagner M. PubMed

Lipids Health Dis. 2007;6:3. Primary sclerosing cholangitis--the arteriosclerosis of the bile duct? Fickert P, Moustafa T, Trauner M. PubMed

Gastroenterology. 2006;130:465-81. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M. PubMed

Am J Pathol. 2006;168:410-22. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Fickert P, Fuchsbichler A, Marschall HU, Wagner M, Zollner G, Krause R, Zatloukal K, Jaeschke H, Denk H, Trauner M. PubMed

Am J Physiol. 2006;290:G923-32. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Zollner G, Wagner M, Moustafa T, Fickert P, Silbert D, Gumhold J, Fuchsbichler A, Halilbasic E, Denk H, Marschall HU, Trauner M. PubMed

J Lipid Res. 2006;47(3):582-92.  Fxr(-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. Marschall HU1, Wagner M, Bodin K, Zollner G, Fickert P, Gumhold J, Silbert D, Fuchsbichler A, Sjövall J, Trauner M. PubMed

J Hepatol. 2005;43:1045-54. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D. PubMed

Gastroenterology. 2005;129:476-85. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, Fuchsbichler A, Benthin L, Grundström R, Gustafsson U, Sahlin S, Einarsson C, Trauner M. PubMed

Am J Physiol. 2005;289:G798-805. Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. Zollner G, Wagner M, Fickert P, Geier A, Fuchsbichler A, Silbert D, Gumhold J, Zatloukal K, Kaser A, Tilg H, Denk H, Trauner M. PubMed

Hepatology. 2005;42:420-30. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Wagner M, Halilbasic E, Marschall HU, Zollner G, Fickert P, Langner C, Zatloukal K, Denk H, Trauner M. PubMed

Liver Int. 2005;25:367-79. Hepatobiliary transporter expression in human hepatocellular carcinoma. Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K, Denk H, Trauner M. PubMed

J Clin Gastroenterol. 2005 ;39:S111-24. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. Trauner M, Wagner M, Fickert P, Zollner G. PubMed

Hepatology. 2005;41:470-7. Cytokine-independent repression of rodent Ntcp in obstructive cholestasis. Geier A, Zollner G, Dietrich CG, Wagner M, Fickert P, Denk H, van Rooijen N, Matern S, Gartung C, Trauner M. PubMed

Gastroenterology. 2004;127:261-74. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, Tilg H, Krause R, Lammert F, Langner C, Zatloukal K, Marschall HU, Denk H, Trauner M. PubMed

Hepatology. 2004;39:117-28. Spontaneous cholecysto- and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis. Lammert F, Wang DQ, Hillebrandt S, Geier A, Fickert P, Trauner M, Matern S, Paigen B, Carey MC. PubMed

J Hepatol. 2003;39:480-8. Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. Zollner G, Fickert P, Fuchsbichler A, Silbert D, Wagner M, Arbeiter S, Gonzalez FJ, Marschall HU, Zatloukal K, Denk H, Trauner M. PubMed

J Hepatol. 2003;38(6):717-27. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, Denk H, Trauner M. PubMed

Gastroenterology. 2002;123:1238-51. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, Marschall HU, Tsybrovskyy O, Zatloukal K, Denk H, Trauner M. PubMed

Gastroenterology. 2002;123:1238-51. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, Marschall HU, Tsybrovskyy O, Zatloukal K, Denk H, Trauner M. PubMed

Am J Physiol. 2002;282:G184-91. Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated mice. Zollner G, Fickert P, Silbert D, Fuchsbichler A, Stumptner C, Zatloukal K, Denk H, Trauner M. PubMed

Gastroenterology. 2001;121:170-83. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M. PubMed

Hepatology. 2001;33:633-46. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L, Ferenci P, Stauber RE, Krejs GJ, Denk H, Zatloukal K, Trauner M. PubMed

Can J Gastroenterol. 2000;14 Suppl D:99D-104D. Hepatocellular bile salt transport: lessons from cholestasis. Trauner M, Fickert P, Stauber RE. PubMed